CAMBRIDGE, Mass., March 14, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced that data from its Phase 1 clinical trial of SMART Linker conjugate CAT-1004 will be presented at the Muscular Dystrophy Association's 2014 Clinical Conference in Chicago, Ill. Catabasis' chief medical officer, Joanne Donovan, M.D., Ph.D., will discuss Duchenne muscular dystrophy (DMD) animal model data and data from a Phase 1 clinical trial during the poster session from 6:00 to 8:00 p.m. CDT on Monday, March 17.
Details of the presentation follow:
- Abstract: 45
- Presenter: Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis
- Title: "CAT-1004, a Novel Anti-Inflammatory Agent Under Development for Treatment of Duchenne Muscular Dystrophy"
- Date: Monday, March 17, 6:00 to 8:00 p.m. CDT
- Location: Hyatt Regency, Chicago, Ill.; Regency Ballroom Foyer
CAT-1004 is a new chemical entity that targets NF-kB, a central mediator of muscle inflammation. There is a growing body of evidence demonstrating inflammation to be critical in the underlying pathology of DMD. CAT-1004 modulates the NF-kB pathway by simultaneously inhibiting pro-inflammatory pathways and activating endogenous anti-inflammatory pathways to resolve inflammation. In preclinical models, CAT-1004 has been shown to reduce degenerating muscle tissue and increase regenerating muscle tissue while reducing muscle inflammation. In longer term preclinical DMD studies, CAT-1004 has been shown to improve muscle function. In early clinical studies, CAT-1004 has been shown to inhibit NF-kB activation and is safe and well tolerated. The unique NF-kB modulatory profile of CAT-1004 leverages Catabasis' proprietary SMART Linker technology to chemically conjugate two NF-kB modulators, the omega-3 fatty acid DHA and salicylate, for selective intracellular delivery and synergistic activity.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, Catabasis conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled an experienced team that is passionately committed to improving the lives of patients. Catabasis was founded in 2008 and is headquartered in Cambridge, Mass.
Please visit www.catabasis.com for more information.
Catabasis Pharmaceuticals Inc.
Tony Russo, Ph.D.
Matt Middleman, M.D.
SOURCE Catabasis Pharmaceuticals Inc.